Imperial College London


Faculty of MedicineSchool of Public Health

Reader in Cardiometabolic Disease Epidemiology



+44 (0)20 7594 3347a.dehghan CV




157Norfolk PlaceSt Mary's Campus






BibTex format

author = {'t, Hart LM and Vogelzangs, N and Mook-Kanamori, DO and Brahimaj, A and Nano, J and van, der Heijden AAWA and Willems, van Dijk K and Slieker, RC and Steyerberg, EW and Ikram, MA and Beekman, M and Boomsma, DI and van, Duijn CM and Slagboom, PE and Stehouwer, CDA and Schalkwijk, CG and Arts, ICW and Dekker, JM and Dehghan, A and Muka, T and van, der Kallen CJH and Nijpels, G and van, Greevenbroek MMJ},
doi = {10.1210/jc.2018-01165},
journal = {J Clin Endocrinol Metab},
pages = {4569--4579},
title = {Blood Metabolomic Measures Associate With Present and Future Glycemic Control in Type 2 Diabetes.},
url = {},
volume = {103},
year = {2018}

RIS format (EndNote, RefMan)

AB - Objective: We studied whether blood metabolomic measures in people with type 2 diabetes (T2D) are associated with insufficient glycemic control and whether this association is influenced differentially by various diabetes drugs. We then tested whether the same metabolomic profiles were associated with the initiation of insulin therapy. Methods: A total of 162 metabolomic measures were analyzed using a nuclear magnetic resonance-based method in people with T2D from four cohort studies (n = 2641) and one replication cohort (n = 395). Linear and logistic regression analyses with adjustment for potential confounders, followed by meta-analyses, were performed to analyze associations with hemoglobin A1c levels, six glucose-lowering drug categories, and insulin initiation during a 7-year follow-up period (n = 698). Results: After Bonferroni correction, 26 measures were associated with insufficient glycemic control (HbA1c >53 mmol/mol). The strongest association was with glutamine (OR, 0.66; 95% CI, 0.61 to 0.73; P = 7.6 × 10-19). In addition, compared with treatment-naive patients, 31 metabolomic measures were associated with glucose-lowering drug use (representing various metabolite categories; P ≤ 3.1 × 10-4 for all). In drug-stratified analyses, associations with insufficient glycemic control were only mildly affected by different glucose-lowering drugs. Five of the 26 metabolomic measures (apolipoprotein A1 and medium high-density lipoprotein subclasses) were also associated with insulin initiation during follow-up in both discovery and replication. The strongest association was observed for medium high-density lipoprotein cholesteryl ester (OR, 0.54; 95% CI, 0.42 to 0.71; P = 4.5 × 10-6). Conclusion: Blood metabolomic measures were associated with present and future glycemic control and might thus provide relevant cues to identify those at increased risk of treatment failure.
AU - 't,Hart LM
AU - Vogelzangs,N
AU - Mook-Kanamori,DO
AU - Brahimaj,A
AU - Nano,J
AU - van,der Heijden AAWA
AU - Willems,van Dijk K
AU - Slieker,RC
AU - Steyerberg,EW
AU - Ikram,MA
AU - Beekman,M
AU - Boomsma,DI
AU - van,Duijn CM
AU - Slagboom,PE
AU - Stehouwer,CDA
AU - Schalkwijk,CG
AU - Arts,ICW
AU - Dekker,JM
AU - Dehghan,A
AU - Muka,T
AU - van,der Kallen CJH
AU - Nijpels,G
AU - van,Greevenbroek MMJ
DO - 10.1210/jc.2018-01165
EP - 4579
PY - 2018///
SP - 4569
TI - Blood Metabolomic Measures Associate With Present and Future Glycemic Control in Type 2 Diabetes.
T2 - J Clin Endocrinol Metab
UR -
UR -
VL - 103
ER -